Different p16^INK4a and p14^ARF Expression Patterns in Acute Myeloid Leukaemia and Normal Blood Leukocytes

References

• Duro D., Bernard O., Delia Valle V., et al. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 1995; 11: 21–29
   PubMed Web of Science ®Google Scholar
• Quelle D. E., Zindy F., Ashmun R. A., Sherr C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993–1000
   PubMed Web of Science ®Google Scholar
• Chin L., Pomerantz J., DePinho R. A. The INK4a/ARF tumor suppressor: one gene—two products—two pathways. Trends Biochem Sci 1998; 23: 291–296
   PubMed Web of Science ®Google Scholar
• Liggett W. H., Jr., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16: 1197–1206
   PubMed Web of Science ®Google Scholar
• Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995; 11: 136–140
   PubMed Web of Science ®Google Scholar
• Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–330
   PubMed Web of Science ®Google Scholar
• Kamijo T., Weber J. D., Zambetti G., et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95: 8292–8297
   PubMed Web of Science ®Google Scholar
• Tao W., Levine A. J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci US A 1999; 96: 6937–6941
   PubMed Web of Science ®Google Scholar
• Lohrum M. A., Ashcroft M., Kubbutat M. H., Vousden K. H. Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol 2000; 2: 179–181
   PubMed Web of Science ®Google Scholar
• Weber J. D., Kuo M. L., Bothner B., et al. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 2000; 20: 2517–2528
   PubMed Web of Science ®Google Scholar
• Quesnel B., Preudhomme C., Philippe N., et al. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995; 85: 657–663
   PubMed Web of Science ®Google Scholar
• Sill H., Goldman J. M., Cross N. C. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85: 2013–2016
   PubMed Web of Science ®Google Scholar
• Hayette S., Thomas X., Bertrand Y., et al. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias. Leukemia 1997; 11: 1696–1699
   PubMed Web of Science ®Google Scholar
• Hirai H., Ogawa S., Hangaishi A., et al. Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias. Leukemia 1997; 11(Suppl 3)358–360
   PubMedGoogle Scholar
• Herman J. G., Merlo A., Mao L., et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525–4530
   PubMed Web of Science ®Google Scholar
• Gardie B., Cayuela J. M., Martini S., Sigaux F. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 1998; 91: 1016–1020
   PubMed Web of Science ®Google Scholar
• Jamal R., Thomas N. S., Gale R. E., Linch D. C. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level. Leukemia 1996; 10: 629–636
   PubMed Web of Science ®Google Scholar
• Drexler H. G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12: 845–859
   PubMed Web of Science ®Google Scholar
• Herman J. G., Civin C. I., Issa J. P., et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837–841
   PubMed Web of Science ®Google Scholar
• Issa J. P., Baylin S. B., Herman J. G. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997; 11(Suppl 1)S7–11
   PubMed Web of Science ®Google Scholar
• Dodge J. E., List A. F., Futscher B. W. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia. Int J Cancer 1998; 78: 561–567
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Chikatsu N., Takahashi S., et al. Expression of p16INK4A and p14ARF in hematological malignancies. Leukemia 1999; 13: 1760–1769
   PubMed Web of Science ®Google Scholar
• Colotta F., Peri G., Villa A., Mantovani A. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage. J Immunol 1984; 132: 936–944
   PubMed Web of Science ®Google Scholar
• Uguccioni M., D'Apuzzo M. Loetscher, et al. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol 1995; 25: 64–68
   PubMed Web of Science ®Google Scholar
• Zhang Y., Xiong Y., Yarbrough W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725–734
   PubMed Web of Science ®Google Scholar
• Vonlanthen S., Heighway J., Tschan M. P., et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998; 17: 2779–2785
   PubMed Web of Science ®Google Scholar
• Becker-Andre M., Hahlbrock K. Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids Res 1989; 17: 9437–9446
   PubMed Web of Science ®Google Scholar
• Schwaller J., Pabst T., Bickel M., et al. Comparative detection and quantitation of human CDK inhibitor mRNA expression of p15INK4B, p16INK4A, p16beta, p18INK4C, p19INK4D, p21WAF1, p27KIP1 and p57KIP2 by RT-PCR using a polycompetitive internal standard. Br J Haematol 1997; 99: 896–900
   PubMed Web of Science ®Google Scholar
• Pabst T., Peters U. R., Tinguely M., et al. Divergent Expression of Cyclin-Dependent Kinase Inhibitors (CKI) and p14ARF/p16β in Non-Hodgkin's Lymphomas and Chronic Lymphocytic Leukemia. Leuk Lymphoma 2000; 37: 639–648
   PubMed Web of Science ®Google Scholar
• Tschan M. P., Peters U. R., Cajot J. F., et al. The cyclin-dependent kinase inhibitors p18INK4c and p19INK4d are highly expressed in CD34+ progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells. Br J Haematol 1999; 106: 644–651
   PubMed Web of Science ®Google Scholar
• Larison K. D., BreMiller R., Wells K. S., et al. Use of a new fluorogenic phosphatase substrate in immunohisto-chemical applications. J Histochem Cytochem 1995; 43: 77–83
   PubMed Web of Science ®Google Scholar
• Stone S., Jiang P., Dayananth P., et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995; 55: 2988–2994
   PubMed Web of Science ®Google Scholar
• Haidar M. A., Cao X. B., Manshouri T., et al. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood 1995; 86: 311–315
   PubMed Web of Science ®Google Scholar
• Nakamaki T., Kawamata N., Schwaller J., et al. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br J Haematol 1995; 91: 139–149
   PubMed Web of Science ®Google Scholar
• Haber D. A. Splicing into senescence: the curious case of p16 and p19ARF. Cell 1997; 91: 555–558
   PubMed Web of Science ®Google Scholar
• Kamijo T., Zindy F., Roussel M. F., et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649–659
   PubMed Web of Science ®Google Scholar
• Olsson I., Bergh G., Ehinger M., Gullberg U. Cell differentiation in acute myeloid leukemia. Eur J Haematol 1996; 57: 1–16
   PubMed Web of Science ®Google Scholar
• Hayashi K., Metzger R., Salonga D., et al. High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach. Oncogene 1997; 15: 1481–1488
   PubMed Web of Science ®Google Scholar
• Van Zee K. J., Calvano J. E., Bisogna M. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 1998; 16: 2723–2727
   PubMed Web of Science ®Google Scholar
• Parry D., Bates S., Mann D. J., Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. Embo J 1995; 14: 503–511
   PubMed Web of Science ®Google Scholar
• Shapiro G. I., Edwards CD., Kobzik L., et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505–509
   PubMed Web of Science ®Google Scholar
• Yeager T., Stadler W., Belair C., et al. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 1995; 55: 493–497
   PubMed Web of Science ®Google Scholar
• Paggi M. G., de Fabritiis P., Bonetto F., et al. The retinoblastoma gene product in acute myeloid leukemia: a possible involvement in promyelocytic leukemia. Cancer Res 1995; 55: 4552–4556
   PubMed Web of Science ®Google Scholar
• Delia Valle V., Duro D., Bernard O., Larsen C. J. The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative beta transcript of the p16INK4a/MTS1 gene. Oncogene 1997; 15: 2475–2481
   PubMed Web of Science ®Google Scholar
• Gazzeri S., Delia Valle V., Chaussade L., et al. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998; 58: 3926–3931
   PubMed Web of Science ®Google Scholar
• Flaman J. M., Frebourg T., Moreau V., et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963–3967
   PubMed Web of Science ®Google Scholar
• Seliger B., Papadileris S., Vogel D., et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 1996; 57: 230–240
   PubMed Web of Science ®Google Scholar
• Nakano Y., Naoe T., Kiyoi H., et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol 2000; 65: 23–31
   PubMed Web of Science ®Google Scholar